^
Association details:
Biomarker:PTEN deletion
Cancer:Prostate Cancer
Drug Class:ATM kinase inhibitor
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Title:

ATM Kinase Inhibition Preferentially Sensitises PTEN-Deficient Prostate Tumour Cells to Ionising Radiation

Published date:
12/30/2020
Excerpt:
Furthermore, combined treatment significantly inhibited PTEN-deficient tumour growth compared to PTEN-expressing counterparts...these findings provide pre-clinical data for future clinical evaluation of ATM inhibitors as a neoadjuvant/adjuvant in combination with radiation therapy in prostate cancer patients harbouring PTEN mutation.
DOI:
10.3390/cancers13010079